

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of

Woodward et al

Serial No: n/a

Filed: Submitted herewith

For: CYCLOPENTANE HEPTANOIC
ACID, 2-CYCLOALKYL OR
ARYLALKYL DERIVATIVES AS
THERAPEUTIC AGENTS

Group Art Unit: 1209

Examiner: M. Cebulak

59391 U.S. PTO

08/876937



PATENT 06/16/97

#3


PRELIMINARY AMENDMENT

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Please cancel claims 2 through 25.

26. (New Claim) A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:



wherein R^1 = hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C_1 - C_{12} alkyl cycloalkyl or aryl; and R^2 = Cl or CF_3 .

27. (New Claim) The method of claim 26, wherein R^1 is selected from the group consisting of H, CH_3 , $CH(CH_3)_2$ and $C(CH_3)_3$.

28. (New Claim) The method of claim 26, wherein R^1 is selected from the group consisting of Na^+ and $CH_3N^+(CH_2OH)_3$.

29. (New Claim) The method of claim 26, wherein R^2 is Cl.


30. (New Claim) The method of claim 27, wherein R^2 is CF_3 .

31. (New Claim) The method of claim 26, wherein between about 0.001 and about 1000 $\mu\text{g}/\text{eye}$ of a compound of formula (I) is administered.

32. (New Claim) The method of claim 31, wherein between about 0.01 and about 100 $\mu\text{g}/\text{eye}$ of a compound of formula (I) is administered.

33. (New Claim) The method of claim 31, wherein between about 0.05 and about 10 $\mu\text{g}/\text{eye}$ of a compound of formula (I) is administered.

34. (New Claim) A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension in primates, comprising a therapeutically effective amount of a compound of formula:



wherein: R^1 = hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C_1 - C_{12} alkyl, cycloalkyl or aryl; and R^2 = Cl or CF_3 .

35. (New Claim) The composition of claim 34, wherein R^1 is selected from the group consisting of H, CH_3 , $CH(CH_3)_2$ and $C(CH_3)_3$.

36. (New Claim) The composition of claim 34, wherein R^1 is selected from the group consisting of Na^+ and $CH_3N^+(CH_2OH)_3$.

37. (New Claim) The composition of claim 34, wherein R^2 is Cl.

B1
Cont.

2025-03-10 10:16:37


38. (New Claim) The composition of claim 34, wherein R^2 is CF_3 .

39. (New Claim) The composition of claim 34, wherein between about 0.001 and about 100 $\mu g/eye$ of a compound of formula (I) is administered.

40. (New Claim) The composition of claim 39, wherein between about 0.01 and about $\mu g/eye$ of a compound of formula (I) is administered.

41. (New Claim) The composition of claim 40, wherein between about 0.05 and about 10 $\mu g/eye$ of a compound of formula (I) is administered.

42. (New Claim) A method of treating glaucoma and ocular hypertension, which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:



wherein: R^1 = a pharmaceutically acceptable ester moiety; and R^2 = Cl or CF_3 .

43. (New Claim) The method of claim 42, wherein R^2 is Cl.

44. (New Claim) The method of claim 42, wherein R^2 is CF_3 .

45. (New Claim) The method of claim 42, wherein between about 0.001 and about 1000 $\mu g/eye$ of a compound of formula (I) is administered.